



August 8, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Subject: Notice and Report pursuant to 18 V.S.A. § 4637(c) and (d)

To the Office of the Attorney General of Vermont:

Pursuant to 18 V.S.A. § 4637(c) and (d), Glenmark Pharmaceuticals Inc., USA (“Glenmark”) is submitting the following information:

NDC Number	Product Description	Date of Commercial Availability	Wholesale Acquisition Cost (As of date of commercial availability)
68462-0421-21	Atovaquone Oral Suspension USP	January 15, 2019	\$800.00
68462-0446-26	Sevelamer Hydrochloride Tablets	February 8, 2019	\$1,158.32
68462-0447-18	Sevelamer Hydrochloride Tablets	February 8, 2019	\$1,158.32

Information pursuant to 18 V.S.A. § 4637(c):

- 1) US and International marketing and pricing plans used at launch:** Glenmark does not make its marketing or pricing plans (other than the wholesale acquisition costs identified above) publicly available, and does not believe that such information is in the public domain. Accordingly, pursuant to 18 V.S.A. § 4637(d), Glenmark will not be providing this information.
- 2) Estimated volume of patients who may be prescribed the drug:** Estimated number of patients is not known.
- 3) Whether the FDA granted breakthrough therapy designation or priority review:** The products did not receive priority review or breakthrough status.
- 4) Date and price of acquisition:** Not applicable. Glenmark developed the products.